Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer

NCT01378598 | Completed DMC

• 1 other identifier: 10-171
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Research has found that patients sometimes have trouble obtaining oral (by mouth) cancer medications, understanding how to take these pills, handling side effects related to these drugs, and remembering to take these medications. The purpose of this research study is to have direct care nurses (DCNs) in the Thoracic Oncology Program (TOP) clinic provide teaching and follow-up to patients starting erlotinib (using a teaching tool) and to test the feasibility of providing education and follow-up. This study will also evaluate if increasing knowledge about erlotinib helps participants manage side effects and stay on their erlotinib without interruptions.

Conditions

Lung Cancer

Keywords

erlotinib; educational intervention; direct care nurse

Outcome Measures

Primary Outcomes (1)

• Feasibility of a DCN educational intervention to enhance participant knowledge

  To test the feasibility of direct care nurse (DCN) educational intervention to enhance participant knowledge of erlotinib and improve patient-reported adherence with regard to: 1) enrollment and retention rates, 2) DCN availability, 3) Completion of educational sessions and 4) Resources used or required for each session

  1 year

Secondary Outcomes (1)

• Describe the knowledge of and adherence to erlotinib as an oral anticancer agent

  1 year

Interventions

Nursing Educational Intervention OTHER

Four educational sessions with the direct care nurse (DCN)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older
• Non-small cell lung cancer diagnosis
• Patient/provider decision to start erlotinib monotherapy
• No prior treatment with erlotinib
• Willingness to follow the protocol visit schedule
• Ability to understand and converse in English
• No major physical or psychological limitation that would interfere with study participation
• Not participating in other studies involving nurse/patient interactions

Sponsors & Collaborators

• Dana-Farber Cancer Institute: lead

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Joan Lucca, RN, MSN, NP-C, AOCN

  Dana-Farber Cancer Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 27, 2010
• First Posted: June 22, 2011
• Study Start: September 1, 2010
• Primary Completion: February 1, 2012
• Study Completion: February 1, 2012
• Last Updated: June 26, 2012

Record last verified: 2012-06